Oxurion NV Business Update - Q3 2018
(WorldNews Belgium)

Shareholders` Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) First Patient enrolled in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) End Q3 2018 cash position EUR95.1 million Highlights Following shareholders` approval on September 3, ThromboGenics NV was rebranded Oxurion NV. The new name Oxurion better reflects the Company`s ambition to deliver best in class therapies for back...